Skip to content
PoliticalRepoPoliticalRepo

Person

Official portrait of Rep. Beatty, Joyce [D-OH-3]

Rep. Beatty, Joyce [D-OH-3]

United States · Official source

Records

3,425 records where Rep. Beatty, Joyce [D-OH-3] is listed as a sponsor, author, or other actor. Search with topics and years

Bill· HRH.R. 8581 (119th)referred

SET Act

United States · United States Congress · 29 April 2026

Bill· HRH.R. 8502 (119th)referred

HARVEST Act

United States · United States Congress · 27 April 2026

Bill· HRH.R. 8503 (119th)referred

Save SNAP Act of 2026

United States · United States Congress · 27 April 2026

Resolution· HRESH.Res. 1162 (119th)referred

Supporting the goals and ideals of Glisten's (formerly GLSEN's) 2026 Day of Silence in bringing attention to anti-LGBTQI+ bullying, harassment, discrimination, and other forms of victimization faced by individuals in schools, and calling communities across the country to action to demand equal educational opportunity, basic civil rights protections, and freedom from erasure for all students, particularly LGBTQI+ young people, in K-12 schools.

United States · United States Congress · 9 April 2026

Bill· HRH.R. 8239 (119th)referred

SACRED Act

United States · United States Congress · 9 April 2026

Bill· HRH.R. 8246 (119th)referred

OHH SNAP Act of 2026

United States · United States Congress · 9 April 2026

Bill· HRH.R. 8205 (119th)open

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

United States · United States Congress · 6 April 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Bill· HRH.R. 8163 (119th)reported

Provider Reimbursement Stability Act of 2026

United States · United States Congress · 30 March 2026

Provider Reimbursement Stability Act of 2026 This bill allows for larger annual adjustments to the Medicare physician fee schedule. It also requires the Centers for Medicare & Medicaid Services (CMS) to make certain corrections to compensate for expenditures under the fee schedule that exceed a certain amount in a given year, and it limits how much certain adjustment factors may vary each year. Current law prohibits annual adjustments to the Medicare physician fee schedule that would result in a more than $20 million difference between the adjusted amount and the non-adjusted amount of total expenditures. The bill increases this threshold to $54.3 million beginning in 2027, with adjustments for inflation every five years beginning in 2032. Additionally, for certain services, the bill requires the CMS to determine the difference between expenditures based on estimated utilization of the service and expenditures based on actual utilization. If this difference exceeds a certain percentage of total expenditures under the fee schedule, the CMS must reconcile this difference by adjusting payments for the following year. This requirement applies to services for which payment was bundled with another service and there was a separate or add-on payment during the previous year. Finally, the CMS must update the prices and rates of each category of direct costs that affect payments (e.g., prices of equipment) at least every five years, with updates made to each category in the same year. The bill also prohibits the CMS from varying a certain adjustment factor by more than 2.5% each year.

Bill· HRH.R. 8074 (119th)referred

Kira Johnson Act

United States · United States Congress · 25 March 2026

Bill· HRH.R. 8080 (119th)referred

Data to Save Moms Act

United States · United States Congress · 25 March 2026

Bill· HRH.R. 8055 (119th)referred

Extending WIC for New Moms Act

United States · United States Congress · 24 March 2026

Extending WIC for New Moms Act This bill amends the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) to extend the eligibility periods for breastfeeding and postpartum women. Specifically, a state program may elect to certify a breastfeeding woman for up to 24 months (currently 1 year) postpartum. The bill also expands the eligibility period for postpartum women to up to 24 months after termination of pregnancy (currently 6 months). The Department of Agriculture must submit a report to Congress evaluating the effect of these changes to the program on (1) maternal and infant health outcomes, (2) breastfeeding rates, and (3) qualitative evaluations of family experiences under WIC. 

Bill· HRH.R. 7973 (119th)referred

Momnibus Act

United States · United States Congress · 18 March 2026

Bill· HRH.R. 7830 (119th)referred

WELLS Act

United States · United States Congress · 5 March 2026

Bill· HRH.R. 7802 (119th)referred

DISCLOSE Act of 2026

United States · United States Congress · 4 March 2026

Democracy Is Strengthened by Casting Light On Spending in Elections Act of 2026 or the DISCLOSE Act of 2026 This bill addresses campaign finance, including by expanding the prohibition on campaign spending by foreign nationals, requiring additional disclosures of campaign expenditures, and requiring additional disclosures regarding certain political advertisements. Specifically, the bill expands existing foreign money prohibitions to include disbursements for paid web-based or digital communications and federal judicial nomination communications. It also prohibits foreign nationals from contributing to campaigns related to ballot initiatives and referenda. The Government Accountability Office must, for each four-year election cycle, study and report on the incidence of illicit foreign money in federal elections. Next, the bill makes it unlawful to establish or use a corporation, company, or other entity with the intent to conceal an election contribution or donation by a foreign national. A violator is subject to criminal penalties—a fine, a prison term of up to five years, or both. Covered organizations (e.g., corporations, labor organizations, and political organizations) must, within 24 hours, file reports with the Federal Election Commission to disclose campaign expenditures of more than $10,000 during an election cycle. The bill also requires organizations to provide additional disclosures regarding political advertisements, including the donors who contributed the most money to that organization in the last year.

Bill· HRH.R. 7769 (119th)referred

MINT Act

United States · United States Congress · 3 March 2026